A 20 years old male from Balochistan, was diagnosed with Chronic Hepatitis B and D, six months back and started on Pegylated Interferon
(Peg IFN) 180 mcg/week.
therapy can delay or prevent HCC in patients of chronic liver disease due to Hepatitis B and C virus even if the patient has not achieved the SVR.
Cassler, who conducted the analysis, adds that the usual course of interferon
therapy for patients with hepatitis C lasts either 24 or 48 weeks, depending on the genotype of the virus, which influences the duration of treatment.
Overall, patients assigned to receive pegylated interferon
alpha-2a for 48 weeks showed a higher rate of sustained virologic response (66%) than those assigned to receive interferon
It means certain patients prone to relapses can qualify for beta interferon
on condition that the NHS is refunded if the treatment fails.
The pegylated alfa-2a interferon
combination led to significantly higher rates of relapse than the consensus interferon
Combining these benefits with the manufacturing advantages provided by the LEX System may result in a far superior and more cost-effective version of alfa interferon
than what is currently commercially available," said Jan Turek, president and CEO of Biolex.
To deliver the interferon
, Grubman and his colleagues engineered harmless viruses to carry a pig interferon
Only long-term follow-up of patients in this and other studies will reveal whether the drug can keep CML at bay indefinitely and continue to spare patients the side effects that have plagued interferon
therapy, Hoffman says.
These long-term tolerability data come as particularly welcome news in conjunction with the American Academy of Neurology guidelines that confirm the effectiveness of interferon
beta-1b in slowing disease progression.
Viragen produces its highly purified, multi-subtype natural alpha interferon
from human white blood cells, a key part of the body's immune system.
The trial compared alpha interferon
at a dosage of 3 million units / day with the same dosage given three times a week.
There was, however, a significant survival difference between patients who stopped taking interferon
at least 90 days before transplant and patients whose treatment was more recent.
The new study, which appears in the current issue of the journal Hepatology, found that in patients who relapsed after receiving conventional interferon
therapy, the disease was three times more likely to go into remission when treated a second time with Infergen.
Our comprehensive report, Interferon
Market Forecast to 2015, says that though the consumption of the interferon
drugs is increasing, the segment is being hit by patent expirations.